Bolt Biotherapeutics Valuation
| BOLT Stock | USD 0.44 0.03 7.32% |
Bolt Biotherapeutics is overvalued. Bolt Biotherapeutics shows a prevailing Real Value of $0.4 per share. The current price of the firm is $0.44. Our model approximates the value of Bolt Biotherapeutics from analyzing the firm fundamentals such as Shares Outstanding of 38.27 M, operating margin of (14.41) %, and Return On Equity of -0.65 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Bolt Biotherapeutics' valuation include:
Price Book 0.2232 | Enterprise Value | Enterprise Value Ebitda 0.9324 | Price Sales 1.8 | Enterprise Value Revenue 270.646 |
Overvalued
Today
Please note that Bolt Biotherapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Bolt Biotherapeutics is based on 3 months time horizon. Increasing Bolt Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Bolt Biotherapeutics' intrinsic value may or may not be the same as its current market price of 0.44, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.44 | Real 0.4 | Target 1.75 | Hype 0.44 | Naive 0.47 |
The intrinsic value of Bolt Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Bolt Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Bolt Biotherapeutics helps investors to forecast how Bolt stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Bolt Biotherapeutics more accurately as focusing exclusively on Bolt Biotherapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Bolt Biotherapeutics' intrinsic value based on its ongoing forecasts of Bolt Biotherapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Bolt Biotherapeutics' closest peers.
Bolt Biotherapeutics Cash |
|
Bolt Valuation Trend
Bolt Biotherapeutics' real value is important for investors to make better decisions and a more accurate overall view of Bolt Biotherapeutics' financial worth over time. Using both Bolt Biotherapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Bolt Biotherapeutics Total Value Analysis
Bolt Biotherapeutics is currently expected to have valuation of (19.55 M) with market capitalization of 17.6 M, debt of 20.22 M, and cash on hands of 176.34 M. The negative valuation of Bolt Biotherapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Bolt Biotherapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(19.55 M) | 17.6 M | 20.22 M | 176.34 M |
Bolt Biotherapeutics Investor Information
About 48.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.22. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bolt Biotherapeutics recorded a loss per share of 1.63. The entity last dividend was issued on the August 29, 2014. The firm had 3:2 split on the January 31, 2008. Based on the key indicators related to Bolt Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Bolt Biotherapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Bolt Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bolt Biotherapeutics has an asset utilization ratio of 4.93 percent. This implies that the Company is making $0.0493 for each dollar of assets. An increasing asset utilization means that Bolt Biotherapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Bolt Biotherapeutics Ownership Allocation
Bolt Biotherapeutics holds a total of 38.27 Million outstanding shares. 30% of Bolt Biotherapeutics outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Bolt Biotherapeutics Profitability Analysis
The company reported the previous year's revenue of 7.88 M. Net Loss for the year was (69.2 M) with loss before overhead, payroll, taxes, and interest of (52.29 M).About Bolt Biotherapeutics Valuation
The stock valuation mechanism determines Bolt Biotherapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Bolt Biotherapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Bolt Biotherapeutics. We calculate exposure to Bolt Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Bolt Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 6.9 M | 7.2 M | |
| Pretax Profit Margin | (7.91) | (8.30) | |
| Operating Profit Margin | (8.71) | (9.14) | |
| Net Loss | (7.91) | (8.30) | |
| Gross Profit Margin | 0.68 | 0.72 |
Bolt Biotherapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Bolt Biotherapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 37.8 M |
Bolt Biotherapeutics Current Valuation Indicators
Bolt Biotherapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Bolt Biotherapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Bolt Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Bolt Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Bolt Biotherapeutics' worth.Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.